

26th December, 2016

The Manager, Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol: PANACEABIO

Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec introduces fully liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib

Dear Sir,


The Company is pleased to announce the launch of Tetravalent Vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib).

The Company is committed to protect children from vaccine-preventable diseases. Easyfour-TT (DTwP-Hib), world's first fully liquid Tetravalent vaccine launched in India, will protect infant from Diphtheria, Tetanus, Whooping Cough and Hib-Meningitis.

Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO Pre-Qualified antigens which ensures good quality, high immunogenicity and less reactogenicity. Being fully liquid, product requires no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.

A copy of the Press Release titled "Panacea Biotec Introduces world's first fully liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib" being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Thanking you,
Sincerely yours,
for **Panacea Biotec Ltd.**


Vinod Goel
Group CFO and Head Legal
& Company Secretary

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Press Release:

Immediate Release

Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib



New Delhi: December 26, 2016: Panacea Biotec, one of India's leading research based health Management Company, is pleased to announce launch of Tetravalent Vaccine **Easyfour-TT** for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib).

Panacea Biotec is committed to protect children from vaccine-preventable diseases, **Easyfour-TT (DTwP-Hib)**, world's first fully liquid Tetravalent vaccine launch in India will protect infant from Diphtheria, Tetanus, Whooping Cough, Hib-Meningitis.

Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO Pre-Qualified antigens which ensures good quality, high immunogenicity and less reactogenicity. Being fully liquid, product requires no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.

Panacea Biotec, one of the largest vaccine manufacturing companies has made immense contribution in disease prevention and reducing child mortality, through innovative vaccine development, production and marketing. The company is well acknowledged by Global Agencies in partnering for Polio eradication program and has supplied over 10 billion doses of WHO Pre-qualified Polio vaccine across developing countries.

Commenting on the occasion, **Dr. Rajesh Jain**, Jt. Managing Director, Panacea Biotec Limited said, Panacea Biotec will remain committed to its mission "**Innovation in Support of Life**" and continue to provide the Latest and Most Affordable preventive and therapeutic care to patients across the globe. Our highly talented and committed scientific team are doing a wonderful job in combining cutting edge scientific know-how and patient understanding to deliver affordable and quality products aimed at improving the overall patient health and well-being.



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: corporate@panaceabiotec.com
CIN: L33117PB1984PLC022350



About Panacea Biotec Ltd.

Panacea Biotec is one of India's leading research based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producers in India and is one of the leading Biotechnology Companies. The Company has also been ranked amongst the top 60 pharmaceutical companies (AIOCD AWACS-MAT MAR-2016) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric immunization vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2) products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastroretentive systems. Panacea Biotec has introduced its products in over 20 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations. The company's state-of-the-art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, European and WHO cGMP standards. The company has around 2,500 employees including around 120 scientists working across 4 R&D centers of the Company.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

For more information, please contact –


Mr. P. D. Karan

Vice President - Corporate Communication & Business Development

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040

Email: pdkaran@panaceabiotec.com

Web: www.panaceabiotec.com



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: corporate@panaceabiotec.com
CIN: L33117PB1984PLC022350